Cargando…
RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1
BACKGROUND: Endothelial barrier dysfunction characterized by hyperpermeability of the vascular endothelium is a key factor in the pathogenesis of chronic inflammatory diseases and affects clinical outcomes. In states of chronic inflammation, mediators secreted by activated immune cells or vascular e...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116367/ https://www.ncbi.nlm.nih.gov/pubmed/30157748 http://dx.doi.org/10.1186/s10020-018-0048-z |
_version_ | 1783351589782683648 |
---|---|
author | Skaria, Tom Bachli, Esther Schoedon, Gabriele |
author_facet | Skaria, Tom Bachli, Esther Schoedon, Gabriele |
author_sort | Skaria, Tom |
collection | PubMed |
description | BACKGROUND: Endothelial barrier dysfunction characterized by hyperpermeability of the vascular endothelium is a key factor in the pathogenesis of chronic inflammatory diseases and affects clinical outcomes. In states of chronic inflammation, mediators secreted by activated immune cells or vascular endothelium may affect the barrier function and permeability of the vascular endothelium. The matricellular R-spondin family member RSPO3 is produced by inflammatory-activated human monocytes and vascular endothelial cells, but its effects in the regulation of vascular endothelial barrier function remains elusive. METHODS: The present study investigates the effects of RSPO3 on the barrier function of adult human primary macro- and micro- vascular endothelial monolayers. Tight monolayers of primary endothelial cells from human coronary and pulmonary arteries, and cardiac, brain, and dermal microvascular beds were treated with RSPO3 either alone or in combination with pro-inflammatory mediator IL-1β. Endothelial barrier function was assessed non-invasively in real-time using Electric Cell-substrate Impedance Sensing. RESULTS: RSPO3 treatment critically affected barrier function by enhancing the permeability of all vascular endothelial monolayers investigated. To confer hyperpermeable phenotype in vascular endothelial monolayers, RSPO3 induced inter-endothelial gap formation by disrupting the β-catenin and VE-cadherin alignment at adherens junctions. RSPO3 synergistically enhanced the barrier impairing properties of the pro-inflammatory mediator IL-1β. CONCLUSION: Here, we show that the matricellular protein RSPO3 is a mediator of endothelial hyperpermeability that can act in synergy with the inflammatory mediator IL-1β. This finding stimulates further studies to delineate the endothelial barrier impairing properties of RSPO3 and its synergistic interaction with IL-1β in chronic inflammatory diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10020-018-0048-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6116367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61163672018-09-04 RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 Skaria, Tom Bachli, Esther Schoedon, Gabriele Mol Med Short Report BACKGROUND: Endothelial barrier dysfunction characterized by hyperpermeability of the vascular endothelium is a key factor in the pathogenesis of chronic inflammatory diseases and affects clinical outcomes. In states of chronic inflammation, mediators secreted by activated immune cells or vascular endothelium may affect the barrier function and permeability of the vascular endothelium. The matricellular R-spondin family member RSPO3 is produced by inflammatory-activated human monocytes and vascular endothelial cells, but its effects in the regulation of vascular endothelial barrier function remains elusive. METHODS: The present study investigates the effects of RSPO3 on the barrier function of adult human primary macro- and micro- vascular endothelial monolayers. Tight monolayers of primary endothelial cells from human coronary and pulmonary arteries, and cardiac, brain, and dermal microvascular beds were treated with RSPO3 either alone or in combination with pro-inflammatory mediator IL-1β. Endothelial barrier function was assessed non-invasively in real-time using Electric Cell-substrate Impedance Sensing. RESULTS: RSPO3 treatment critically affected barrier function by enhancing the permeability of all vascular endothelial monolayers investigated. To confer hyperpermeable phenotype in vascular endothelial monolayers, RSPO3 induced inter-endothelial gap formation by disrupting the β-catenin and VE-cadherin alignment at adherens junctions. RSPO3 synergistically enhanced the barrier impairing properties of the pro-inflammatory mediator IL-1β. CONCLUSION: Here, we show that the matricellular protein RSPO3 is a mediator of endothelial hyperpermeability that can act in synergy with the inflammatory mediator IL-1β. This finding stimulates further studies to delineate the endothelial barrier impairing properties of RSPO3 and its synergistic interaction with IL-1β in chronic inflammatory diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10020-018-0048-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-29 /pmc/articles/PMC6116367/ /pubmed/30157748 http://dx.doi.org/10.1186/s10020-018-0048-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Skaria, Tom Bachli, Esther Schoedon, Gabriele RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title | RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title_full | RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title_fullStr | RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title_full_unstemmed | RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title_short | RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1 |
title_sort | rspo3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory il-1 |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116367/ https://www.ncbi.nlm.nih.gov/pubmed/30157748 http://dx.doi.org/10.1186/s10020-018-0048-z |
work_keys_str_mv | AT skariatom rspo3impairsbarrierfunctionofhumanvascularendothelialmonolayersandsynergizeswithproinflammatoryil1 AT bachliesther rspo3impairsbarrierfunctionofhumanvascularendothelialmonolayersandsynergizeswithproinflammatoryil1 AT schoedongabriele rspo3impairsbarrierfunctionofhumanvascularendothelialmonolayersandsynergizeswithproinflammatoryil1 |